<?xml version="1.0" encoding="UTF-8"?>
<ref id="CR23">
 <label>23.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Burnett</surname>
    <given-names>AK</given-names>
   </name>
   <name>
    <surname>Russell</surname>
    <given-names>NH</given-names>
   </name>
   <name>
    <surname>Hills</surname>
    <given-names>RK</given-names>
   </name>
   <name>
    <surname>Bowen</surname>
    <given-names>D</given-names>
   </name>
   <name>
    <surname>Kell</surname>
    <given-names>J</given-names>
   </name>
   <name>
    <surname>Knapper</surname>
    <given-names>S</given-names>
   </name>
   <name>
    <surname>Morgan</surname>
    <given-names>YG</given-names>
   </name>
   <name>
    <surname>Lok</surname>
    <given-names>J</given-names>
   </name>
   <name>
    <surname>Grech</surname>
    <given-names>A</given-names>
   </name>
   <name>
    <surname>Jones</surname>
    <given-names>G</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): Results of a randomised, controlled, phase 3 trial</article-title>
  <source>Lancet Oncol.</source>
  <year>2015</year>
  <volume>16</volume>
  <issue>13</issue>
  <fpage>1295</fpage>
  <lpage>1305</lpage>
  <pub-id pub-id-type="doi">10.1016/S1470-2045(15)00193-X</pub-id>
  <?supplied-pmid 26384238?>
  <pub-id pub-id-type="pmid">26384238</pub-id>
 </element-citation>
</ref>
